1 / 21

Table of Content - Global Prostate Cancer Testing Market

The global prostate cancer testing market was valued at $5,246.9 million in 2021, and it is expected to reach $21,306.9 million by 2032, growing at a CAGR of 13.68% during the forecast period 2022-2032.

bisreports
Download Presentation

Table of Content - Global Prostate Cancer Testing Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. res Global Prostate Cancer Testing Market - A Regional and Country Analysis Table of Content GLOBAL PROSTATE CANCER TESTING MARKET Focus on Test Type, Application, End User, and Region Analysis and Forecast: 2022-2032 December 2022 1 All rights reserved at BIS Research Inc.

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. GLOBAL PROSTATE CANCER TESTING MARKET Copyright © 2022 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. 2 All rights reserved at BIS Research Inc.

  3. Table of Content Executive Summary .......................................................................... 22 1.Markets ..................................................................................... 27 1.1 Product Definition ............................................................................................ 28 1.1.1Inclusion and Exclusion Criteria ................................................................ 28 1.2 Market Scope ................................................................................................... 28 1.2.1Scope of the Study ...................................................................................... 28 1.2.2Key Questions Answered in the Report .................................................... 29 1.3 Research Methodology ................................................................................... 30 1.3.1Global Prostate Cancer Testing Market: Research Methodology ........... 30 1.3.2Data Sources ............................................................................................... 31 1.3.2.1 Primary Data Sources ........................................................................................ 31 1.3.2.2 Secondary Data Sources ................................................................................... 32 1.3.3Market Estimation Model ............................................................................ 32 1.3.4Criteria for Company Profiling ................................................................... 34 1.4 Market: Overview ............................................................................................. 35 1.4.1Market Definition ......................................................................................... 35 1.4.2Market Footprint and Growth Potential ..................................................... 36 1.4.3Future Potential ........................................................................................... 37 1.4.4COVID-19 Impact on Global Prostate Cancer Testing Market ................. 37 2. Industry Analysis ...................................................................... 39 GLOBAL PROSTATE CANCER TESTING MARKET 2.1 Overview ........................................................................................................... 40 2.2 Legal Requirements and Framework in the U.S. ........................................... 40 2.2.1National Comprehensive Cancer Network (NCCN) Guidelines ............... 40 2.2.2American Urological Association (AUA) ................................................... 41 2.2.3American Cancer Society (ACS) ................................................................ 43 2.2.4U.S. Preventive Services Task Force (USPSTF) ....................................... 43 2.3 Legal Requirements and Framework in Europe ............................................ 44 2.4 Legal Requirements and Framework in Asia-Pacific .................................... 45 3 All rights reserved at BIS Research Inc.

  4. 2.4.1China ............................................................................................................ 45 2.5 Patent Analysis ................................................................................................ 46 2.5.1Patent Filing Trend ...................................................................................... 46 2.5.2Patent Analysis (by Year) ........................................................................... 46 2.5.3Patent Analysis (by Region) ....................................................................... 47 2.5.4Patent Analysis (by Country) ..................................................................... 47 3.Global Prostate Cancer Testing Market: Market Dynamics ......... 48 3.1 Overview ........................................................................................................... 49 3.1.1Impact Analysis ........................................................................................... 49 3.2 Market Drivers .................................................................................................. 50 3.2.1Rising Prevalence of Prostate Cancer Globally ........................................ 50 3.2.1.1 Disease Trend ................................................................................................... 50 3.2.1.2 Increasing Number of Prostate Cancer Screening and Testing ........................ 51 3.2.1.3 Government Initiatives Related to Prostate Cancer ........................................... 52 3.2.2Market Restraints ........................................................................................ 53 3.2.2.1 Probability of False Positive Results of Prostate Cancer Testing ...................... 53 3.2.2.2 Clinical Gaps Related to Prostate Cancer Testing ............................................ 53 3.2.3Market Opportunities .................................................................................. 53 3.2.3.1 New Treatment Therapy and Technique for Prostate Cancer ........................... 53 4.Global Prostate Cancer Testing Market: Competitive Landscape ................................................................................. 54 GLOBAL PROSTATE CANCER TESTING MARKET 4.1 Overview ........................................................................................................... 55 4.2 Corporate Strategies ....................................................................................... 55 4.2.1Mergers and Acquisitions ........................................................................... 55 4.2.2Synergistic Activities .................................................................................. 57 4.2.3Business Expansions and Funding ........................................................... 58 4.3 Business Strategies ........................................................................................ 59 4.3.1Product Launches and Approvals ............................................................. 59 4.3.2Publications ................................................................................................. 61 4.3.3Licenses and Agreements .......................................................................... 62 4 All rights reserved at BIS Research Inc.

  5. 4.3.4Other Activities ............................................................................................ 63 Market Share Analysis .................................................................................... 65 5.Global Prostate Cancer Testing Market (by Test Type), Value ($million), 2021-2032 ................................................................. 67 4.4 5.1 Overview ........................................................................................................... 68 5.2 Pre-biopsy Test ................................................................................................ 69 5.2.1Biomarker Test ............................................................................................ 70 5.2.1.1 Blood-Based ...................................................................................................... 72 5.2.1.2 Urine-Based ....................................................................................................... 75 5.2.2Imaging Test ................................................................................................ 77 5.3 Biopsy ............................................................................................................... 80 5.4 Post-Biopsy Test ............................................................................................. 82 5.4.1Tissue-Based Biomarker Test .................................................................... 83 6.Global Prostate Cancer Testing Market (by Application), Value ($Million), 2021-2032 .................................................................. 85 6.1 Overview ........................................................................................................... 86 6.2 Clinical .............................................................................................................. 87 Research .......................................................................................................... 88 7.Global Prostate Cancer Testing Market (by End User), Value ($Million), 2021-2032 .................................................................. 90 6.3 7.1 Overview ........................................................................................................... 91 GLOBAL PROSTATE CANCER TESTING MARKET 7.2 Cancer Research Institutes ............................................................................. 92 7.3 Diagnostic Laboratories .................................................................................. 93 7.4 Hospitals and Clinics ...................................................................................... 94 7.5 Ambulatory Surgical Centers (ASCs) ............................................................ 95 Others ............................................................................................................... 96 8.Global Prostate Cancer Testing Market (by Region), Value ($Million), 2021-2032 .................................................................. 97 7.6 8.1 Overview ........................................................................................................... 98 8.2 North America ................................................................................................ 101 8.2.1U.S. ............................................................................................................. 103 5 All rights reserved at BIS Research Inc.

  6. 8.2.2Canada ....................................................................................................... 105 8.3 Europe ............................................................................................................ 109 8.3.1Germany ..................................................................................................... 111 8.3.2France ......................................................................................................... 112 8.3.3U.K. ............................................................................................................. 114 8.3.4Italy ............................................................................................................. 116 8.3.5Spain ........................................................................................................... 118 8.3.6Netherlands ................................................................................................ 119 8.3.7Rest-of-Europe........................................................................................... 121 8.4 Asia-Pacific .................................................................................................... 124 8.4.1China .......................................................................................................... 126 8.4.2Japan .......................................................................................................... 127 8.4.3India ............................................................................................................ 129 8.4.4Australia ..................................................................................................... 130 8.4.5South Korea ............................................................................................... 132 8.4.6Rest-of-Asia-Pacific (RoAPAC) ................................................................ 133 8.5 Latin America ................................................................................................. 137 8.5.1Brazil ........................................................................................................... 138 8.5.2Mexico ........................................................................................................ 140 8.5.3Rest-of-Latin America ............................................................................... 142 GLOBAL PROSTATE CANCER TESTING MARKET 8.6 Rest-of-the-World (RoW) ............................................................................... 143 9. Company Profiles .................................................................... 144 9.1 Overview ......................................................................................................... 145 9.2 Abbott. ............................................................................................................ 146 9.2.1Company Overview ................................................................................... 146 9.2.2Role of Abbott. in the Global Prostate Cancer Testing Market.............. 146 9.2.3Key Competitors of the Company ............................................................ 147 9.2.4Financials ................................................................................................... 147 9.2.5Key Insights about the Financial Health of the Company ...................... 149 9.2.6Analyst Perspective .................................................................................. 149 6 All rights reserved at BIS Research Inc.

  7. 9.3 Abcam plc. ...................................................................................................... 150 9.3.1Company Overview ................................................................................... 150 9.3.2Role of Abcam plc. in the Global Prostate Cancer Testing Market ....... 150 9.3.3Key Customers of the Company .............................................................. 152 9.3.4Key Competitors of the Company ............................................................ 152 9.3.5Financials ................................................................................................... 152 9.3.6Analyst Perspective .................................................................................. 154 9.4 Agilent Technologies, Inc. ............................................................................ 155 9.4.1Company Overview ................................................................................... 155 9.4.2Role of Agilent Technologies, Inc. in the Global Prostate Cancer Testing Market ........................................................................................... 155 9.4.3Key Competitors of the Company ............................................................ 156 9.4.4Financials ................................................................................................... 156 9.4.5Analyst Perspective .................................................................................. 159 9.5 Bio-Techne. (ExoDx) ...................................................................................... 160 9.5.1Company Overview ................................................................................... 160 9.5.2Role of Bio-Techne. (ExoDx) in the Global Prostate Cancer Testing Market ......................................................................................................... 160 9.5.3Key Competitors of the Company ............................................................ 161 9.5.4Financials ................................................................................................... 161 9.5.5Key Insights about the Financial Health of the Company ...................... 163 GLOBAL PROSTATE CANCER TESTING MARKET 9.5.6Corporate Strategies ................................................................................. 163 9.5.7Business Strategies .................................................................................. 164 9.5.8Analyst Perspective .................................................................................. 164 9.6 Cleveland Diagnostics, Inc. .......................................................................... 165 9.6.1Company Overview ................................................................................... 165 9.6.2Role of Cleveland Diagnostics, Inc. in the Global Prostate Cancer Testing Market ........................................................................................... 165 9.6.3Key Competitors of the Company ............................................................ 166 9.6.4Corporate Strategies ................................................................................. 166 7 All rights reserved at BIS Research Inc.

  8. 9.6.5Business Strategies .................................................................................. 166 9.6.6Analyst Perspective .................................................................................. 166 9.7 Danaher. (Beckman Coulter, Inc.) ................................................................ 167 9.7.1Company Overview ................................................................................... 167 9.7.2Role of Danaher. (Beckman Coulter, Inc.) in the Global Prostate Cancer Testing Market .............................................................................. 167 9.7.3Key Competitors of the Company ............................................................ 168 9.7.4Financials ................................................................................................... 168 9.7.5Key Insights about the Financial Health of the Company ...................... 170 9.7.6Analyst Perspective .................................................................................. 171 9.8 Exact Sciences Corporation ......................................................................... 172 9.8.1Company Overview ................................................................................... 172 9.8.2Role of Exact Sciences Corporation in the Global Prostate Cancer Testing Market ........................................................................................... 172 9.8.3Key Customers of the Company .............................................................. 173 9.8.4Key Competitors of the Company ............................................................ 173 9.8.5Financials ................................................................................................... 173 9.8.6Key Insights about the Financial Health of the Company ...................... 175 9.8.7Corporate Strategies ................................................................................. 176 9.8.8Business Strategies .................................................................................. 176 9.8.9Analyst Perspective .................................................................................. 177 GLOBAL PROSTATE CANCER TESTING MARKET 9.9 F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.) ..................... 178 9.9.1Company Overview ................................................................................... 178 9.9.2Role of F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.) in the Global Prostate Cancer Testing Market ........................................ 178 9.9.3Key Competitors of the Company ............................................................ 179 9.9.4Financials ................................................................................................... 180 9.9.5Key Insights about the Financial Health of the Company ...................... 182 9.9.6Corporate Strategies ................................................................................. 182 9.9.7Business Strategies .................................................................................. 183 8 All rights reserved at BIS Research Inc.

  9. 9.9.8Analyst Perspective .................................................................................. 183 9.10H.U. Group Holdings, Inc. (Fujeribio) ........................................................... 184 9.10.1Company Overview ................................................................................... 184 9.10.2Role of H.U. Group Holdings, Inc. (Fujeribio) in the Global Prostate Cancer Testing Market .............................................................................. 184 9.10.3Key Competitors of the Company ............................................................ 185 9.10.4Financials ................................................................................................... 185 9.10.5Analyst Perspective .................................................................................. 187 9.11mdxhealth. ...................................................................................................... 188 9.11.1Company Overview ................................................................................... 188 9.11.2Role of mdxhealth. in the Global Prostate Cancer Testing Market ....... 188 9.11.3Financials ................................................................................................... 189 9.11.4Key Insights about the Financial Health of the Company ...................... 190 9.11.5Corporate Strategies ................................................................................. 190 9.11.5.1 Mergers and Acquisitions ................................................................................ 190 9.11.6Business Strategies .................................................................................. 191 9.11.7Analyst Perspective .................................................................................. 191 9.12Siemens Healthcare GmbH ........................................................................... 192 9.12.1Company Overview ................................................................................... 192 9.12.2Role of Siemens Healthcare GmbH in the Global Prostate Cancer Testing Market ........................................................................................... 192 GLOBAL PROSTATE CANCER TESTING MARKET 9.12.3Key Competitors of the Company ............................................................ 193 9.12.4Financials ................................................................................................... 194 9.12.5Key Insights about the Financial Health of the Company ...................... 196 9.12.6Analyst Perspective .................................................................................. 196 9.13Myriad Genetics, Inc. ..................................................................................... 197 9.13.1Company Overview ................................................................................... 197 9.13.2Role of Myriad Genetics, Inc. in the Global Prostate Cancer Testing Market ......................................................................................................... 197 9.13.3Key Competitors of the Company ............................................................ 197 9 All rights reserved at BIS Research Inc.

  10. 9.13.4Corporate Strategies ................................................................................. 198 9.13.5Business Strategies .................................................................................. 198 9.13.6Financials ................................................................................................... 199 9.13.7Key Insights about the Financial Health of the Company ...................... 200 9.13.8Analyst Perspective .................................................................................. 200 9.14NeoGenomics Laboratories. ......................................................................... 201 9.14.1Company Overview ................................................................................... 201 9.14.2Role of NeoGenomics Laboratories. in the Global Prostate Cancer Testing Market ........................................................................................... 201 9.14.3Key Competitors of the Company ............................................................ 202 9.14.4Financials ................................................................................................... 203 9.14.5Key Insights about the Financial Health of the Company ...................... 204 9.14.6Business Strategies .................................................................................. 204 9.14.7Analyst Perspective .................................................................................. 204 9.15OPKO Health, Inc. (GenPath) ........................................................................ 206 9.15.1Company Overview ................................................................................... 206 9.15.2Role of OPKO Health, Inc. (GenPath) in the Global Prostate Cancer Testing Market ........................................................................................... 206 9.15.3Key Customers of the Company .............................................................. 207 9.15.4Key Competitors of the Company ............................................................ 207 9.15.5Financials ................................................................................................... 208 GLOBAL PROSTATE CANCER TESTING MARKET 9.15.6Key Insights about the Financial Health of the Company ...................... 209 9.15.7Corporate Strategies ................................................................................. 210 9.15.8Business Strategies .................................................................................. 210 9.15.9Analyst Perspective .................................................................................. 210 9.16Veracyte, Inc. .................................................................................................. 212 9.16.1Company Overview ................................................................................... 212 9.16.2Role of Veracyte, Inc. in the Global Prostate Cancer Testing Market ......................................................................................................... 212 9.16.3Key Customers of the Company .............................................................. 213 10 All rights reserved at BIS Research Inc.

  11. 9.16.4Key Competitors of the Company ............................................................ 213 9.16.5Financials ................................................................................................... 214 9.16.6Corporate Strategies ................................................................................. 216 9.16.7Analyst Perspective .................................................................................. 218 9.17Emerging Companies .................................................................................... 219 9.17.1Exact imaging ............................................................................................ 219 9.17.2Proteomedix ............................................................................................... 219 9.17.3Gregor Diagnostics ................................................................................... 220 GLOBAL PROSTATE CANCER TESTING MARKET 11 All rights reserved at BIS Research Inc.

  12. List of Figures Figure 1:Tests Related to Prostate Cancer Figure 2:Global Prostate Cancer Testing Market Segmentation Figure 3:Share of Global Prostate Cancer Testing Market (by Test Type), $Million, 2021 and 2032 Figure 4:Share of Global Prostate Cancer Testing Market (by Application), $Million, 2021 and 2032 Figure 5:Share of Global Prostate Cancer Testing Market (by End User), $Million, 2021 and 2032 Figure 6:Global Prostate Cancer Testing Market Segmentation Figure 7:Global Prostate Cancer Testing Market: Research Methodology Figure 8:Primary Research Methodology Figure 9:Bottom-Up Approach (Segment-Wise Analysis) Figure 10:Top-Down Approach (Segment-Wise Analysis) Figure 11:Workflow of Prostate Cancer Testing (NCCN Guidelines) Figure 12:NCCN Guidelines for Prostate Cancer Propose Germline Testing for Patients Figure 13:Year-Wise Analysis of Patents Related to Global Prostate Cancer Testing, January 2019- November 2022 Figure 14:Region-Wise Analysis of Patents Related to Prostate Cancer Testing, January 2019-November 2022 Figure 15:Country-Wise Analysis of Patents Related to Prostate Cancer Testing, January 2019-November 2022 Figure 16:Global Prostate Cancer Testing Market - Market Dynamics Figure 17:Likert Scale Figure 18:Impact Analysis of Market Drivers and Market Challenges on the Global Prostate Cancer Testing GLOBAL PROSTATE CANCER TESTING MARKET Market Figure 19:Trend of New Cases and Death Rate Related to Prostate Cancer Market Figure 20:Share of Key Developments, January 2019-November 2022 Figure 21:Share of Mergers and Acquisitions (by Company), January 2019-November 2022 Figure 22:Share of Synergistic Activities (by Company), January 2019-November 2022 Figure 23:Number of Business Expansions and Funding Activities (by Company), January 2019-November 2022 Figure 24:Number of Product Launches and Approvals (by Company), January 2019-November 2022 Figure 25:Share of Publications (by Company), January 2019-November 2022 Figure 26:Number of Licenses and Agreements (by Company), January 2019-November 2022 12 All rights reserved at BIS Research Inc.

  13. Figure 27:Number of Other Activities (by Company), January 2019-November 2022 Figure 28:Market Share Analysis of Global Prostate Cancer Testing Market (Pre-Biopsy Testing), 2021 Figure 29:Market Share Analysis of Global Prostate Cancer Testing Market (Post-Biopsy Tissue Testing), 2021 Figure 30:Global Prostate Cancer Testing Market (by Test Type) Figure 31:Share of Global Prostate Cancer Testing Market (by Test Type), $Million, 2021 and 2032 Figure 32:Global Prostate Cancer Testing Market (Pre-Biopsy Test), $Million, 2021-2032 Figure 33:Phases of Biomarker Figure 34:Classification of Biomarker Figure 35:Biomarker Test: Prostate Cancer Figure 36:Biomarker Testing: Goals Figure 37:Global Prostate Cancer Testing Market (Biomarker Test), $Million, 2021-2032 Figure 38:Global Prostate Cancer Testing Market (Blood-Based), $Million, 2021-2032 Figure 39:Global Prostate Cancer Testing Market (Urine-Based), $Million, 2021-2032 Figure 40:Advantages of Imaging Test: Prostate Cancer Figure 41:Imaging Test: Prostate Cancer Figure 42:Advantages of mp-MRI Figure 43:Global Prostate Cancer Testing Market (Imaging Test), $Million, 2021-2032 Figure 44:Uses of TRUS-Based Biopsy Figure 45:Prostate Biopsy Methods Figure 46:Global Prostate Cancer Testing Market (Biopsy), $Million, 2021-2032 Figure 47:Global Prostate Cancer Testing Market (Post-Biopsy Test), $Million, 2021-2032 GLOBAL PROSTATE CANCER TESTING MARKET Figure 48:Utility of Tissue-Based Biomarker in Prostate Cancer Management Figure 49:Global Prostate Cancer Testing Market (Tissue-Based Biomarker Test), $Million, 2021-2032 Figure 50:Share of global Prostate Cancer Testing Market (by Application), $Million, 2021 and 2032 Figure 51:Global Prostate Cancer Testing Market (Clinical), $Million, 2021-2032 Figure 52:Global Prostate Cancer Testing Market (Research), $Million, 2021-2032 Figure 53:Global Prostate Cancer Testing Market (by End User) Figure 54:Share of Global Prostate Cancer Testing Market (by End User), $Million, 2021 and 2032 Figure 55:Global Prostate Cancer Testing Market (Cancer Research Institute), $Million, 2021-2032 Figure 56:Global Prostate Cancer Testing Market (Diagnostic Laboratories), $Million, 2021-2032 Figure 57:Global Prostate Cancer Testing Market (Hospitals and Clinics), $Million, 2021-2032 Figure 58:Global Prostate Cancer Testing Market (Ambulatory Surgical Centers), $Million, 2021-2032 13 All rights reserved at BIS Research Inc.

  14. Figure 59:Global Prostate Cancer Testing Market (Others), $Million, 2021-2032 Figure 60:Global Prostate Cancer Testing Market Snapshot (by Region) Figure 61:Global Prostate Cancer Testing Market (by Region), $Million, 2022-2032 Figure 62:North America Prostate Cancer Testing Market, $Million, 2022-2032 Figure 63:North America: Market Dynamics Figure 64:North America Prostate Cancer Testing Market (by Country), $Million, 2021-2032 Figure 65:U.S. Prostate Cancer Testing Market, $Million, 2021-2032 Figure 66:U.S. Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 67:Canada Prostate Cancer Testing Market, $Million, 2022-2032 Figure 68:Canada Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 69:Europe Prostate Cancer Testing Market, $Million, 2022-2032 Figure 70:Europe: Market Dynamics Figure 71:Europe Prostate Cancer Testing Market (by Country), $Million, 2021-2032 Figure 72:Germany Prostate Cancer Testing Market, $Million, 2021-2032 Figure 73:Germany Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 74:France Prostate Cancer Testing Market, $Million, 2021-2032 Figure 75:France Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 76:U.K. Prostate Cancer Testing Market, $Million, 2021-2032 Figure 77:U.K. Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 78:Italy Prostate Cancer Testing Market, $Million, 2021-2032 Figure 79:Italy Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 80:Spain Prostate Cancer Testing Market, $Million, 2021-2032 GLOBAL PROSTATE CANCER TESTING MARKET Figure 81:Spain Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 82:Netherlands Prostate Cancer Testing Market, $Million, 2021-2032 Figure 83:Netherlands Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 84:Rest-of-Europe Prostate Cancer Testing Market, $Million, 2021-2032 Figure 85:Rest-of-Europe Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 86:Asia-Pacific Prostate Cancer Testing Market, $Million, 2022-2032 Figure 87:Asia-Pacific: Market Dynamics Figure 88:Asia-Pacific Prostate Cancer Testing Market (by Country), $Million, 2021-2032 Figure 89:China Prostate Cancer Testing Market, $Million, 2021-2032 Figure 90:China Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 91:Japan Prostate Cancer Testing Market, $Million, 2021-2032 14 All rights reserved at BIS Research Inc.

  15. Figure 92:Japan Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 93:India Prostate Cancer Testing Market, $Million, 2021-2032 Figure 94:India Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 95:Australia Prostate Cancer Testing Market, $Million, 2021-2032 Figure 96:Australia Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 97:South Korea Prostate Cancer Testing Market, $Million, 2021-2032 Figure 98:South Korea Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 99:Rest-of-Asia-Pacific Korea Prostate Cancer Testing Market, $Million, 2021-2032 Figure 100:Rest-of-Asia-Pacific Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 101:Latin America Prostate Cancer Testing Market, $Million, 2022-2032 Figure 102:Latin America: Market Dynamics Figure 103:Latin America Prostate Cancer Testing Market (by Country), $Million, 2021-2032 Figure 104:Brazil Prostate Cancer Testing Market, $Million, 2021-2032 Figure 105:Brazil Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 106:Mexico Prostate Cancer Testing Market, $Million, 2021-2032 Figure 107:Mexico Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 108:Rest-of-Latin America Prostate Cancer Testing Market, $Million, 2021-2032 Figure 109:Rest-of-Latin America Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032 Figure 110:Rest-of-the-World Prostate Cancer Testing Market, $Million, 2022-2032 Figure 111:Total Number of Companies Profiled Figure 112:Abbott.: Product Portfolio Figure 113:Abbott.: Overall Financials, $Million, 2019-2021 GLOBAL PROSTATE CANCER TESTING MARKET Figure 114:Abbott.: Revenue (by Segment), $Million, 2019-2021 Figure 115:Abbott.: Revenue (by Region), $Million, 2019-2021 Figure 116:Abbott.: R&D Expenditure, $Million, 2019-2021 Figure 117:Abcam plc.: Product Portfolio Figure 118:Abcam plc.: Overall Financials, $Million, 2018-2020 Figure 119:Abcam plc.: Revenue (by Segment), $Million, 2019-2020 Figure 120:Abcam plc.: Revenue (by Region), $Million, 2018-2020 Figure 121:Abcam plc.: R&D Expenditure, $Million, 2019-2021 Figure 122:Agilent Technologies, Inc.: Product Portfolio Figure 123:Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021 Figure 124:Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021 15 All rights reserved at BIS Research Inc.

  16. Figure 125:Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 126:Agilent Technologies, Inc: R&D Expenditure, $Million, 2019-2021 Figure 127:Bio-Techne. (ExoDx): Product Portfolio Figure 128:Bio-Techne. (ExoDx): Overall Financials, $Million, 2020-2022 Figure 129:Bio-Techne. (ExoDx): Revenue (by Segment), $Million, 2020-2022 Figure 130:Bio-Techne. (ExoDx): Revenue (by Region), $Million, 2020-2022 Figure 131:Bio-Techne. (ExoDx): R&D Expenditure, $Million, 2020-2022 Figure 132:Cleveland Diagnostics, Inc.: Product Portfolio Figure 133:Danaher. (Beckman Coulter, Inc.): Product Portfolio Figure 134:Danaher. (Beckman Coulter, Inc.): Overall Financials, $Million, 2019-2021 Figure 135:Danaher. (Beckman Coulter, Inc.): Revenue (by Segment), $Million, 2019-2021 Figure 136:Danaher. (Beckman Coulter, Inc.): Revenue (by Region), $Million, 2019-2021 Figure 137:Danaher. (Beckman Coulter, Inc.): R&D Expenditure, $Million, 2019-2021 Figure 138:Exact Sciences Corporation: Product Portfolio Figure 139:Exact Sciences Corporation: Overall Financials, $Million, 2019-2021 Figure 140:Exact Sciences Corporation.: Revenue (by Segment), $Million, 2019-2021 Figure 141:Exact Sciences Corporation: Revenue (by Region), $Million, 2019-2021 Figure 142:Exact Sciences Corporation: R&D Expenditure, $Million, 2019-2021 Figure 143:F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Product Portfolio Figure 144:F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Overall Financials, $Million, 2019-2021 Figure 145:F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Revenue (by Segment), $Million, 2019-2021 GLOBAL PROSTATE CANCER TESTING MARKET Figure 146:F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Revenue (by Region), $Million, 2019-2021 Figure 147:F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): R&D Expenditure, $Million, 2019-2021 Figure 148:H.U. Group Holdings, Inc. (Fujeribio): Product Portfolio Figure 149:H.U. Group Holdings, Inc. (Fujeribio): Overall Financials, $Million, 2018-2020 Figure 150:H.U. Group Holdings, Inc. (Fujeribio): Revenue (by Segment), $Million, 2019-2021 Figure 151:H.U. Group Holdings, Inc. (Fujeribio): R&D Expenditure, $Million, 2018-2020 Figure 152:mdxhealth.: Product Portfolio Figure 153:mdxhealth.: Overall Financials, $Million, 2019-2021 16 All rights reserved at BIS Research Inc.

  17. Figure 154:mdxhealth.: Revenue (by Segment), $Million, 2019-2021 Figure 155:mdxhealth.: R&D Expenditure, $Million, 2019-2021 Figure 156:Siemens Healthcare GmbH: Product Portfolio Figure 157:Siemens Healthcare GmbH: Overall Financials, $Million, 2019-2021 Figure 158:Siemens Healthcare GmbH: Revenue (by Segment), $Million, 2019-2021 Figure 159:Siemens Healthcare GmbH: Revenue (by Region), $Million, 2019-2021 Figure 160:Siemens Healthcare GmbH: R&D Expenditure, $Million, 2019-2021 Figure 161:Myriad Genetics, Inc.: Product Portfolio Figure 162:Myriad Genetics, Inc.: Overall Financials, $Million, 2019-2021 Figure 163:Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 164:Myriad Genetics, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 165:NeoGenomics Laboratories.: Product Portfolio Figure 166:NeoGenomics Laboratories.: Overall Financials, $Million, 2019-2021 Figure 167:NeoGenomics Laboratories.: Revenue (by Segment), $Million, 2019-2021 Figure 168:NeoGenomics Laboratories.: R&D Expenditure, $Million, 2019-2021 Figure 169:OPKO Health, Inc. (GenPath): Product Portfolio Figure 170:OPKO Health, Inc. (GenPath): Overall Financials, $Million, 2019-2021 Figure 171:OPKO Health, Inc. (GenPath): Revenue (by Segment), $Million, 2019-2021 Figure 172:OPKO Health, Inc. (GenPath): R&D Expenditure, $Million, 2019-2021 Figure 173:Veracyte, Inc.: Product Portfolio Figure 174:Veracyte, Inc.: Overall Financials, $Million, 2019-2021 Figure 175:Veracyte, Inc.: Revenue (by Segment), $Million, 2019-2021 GLOBAL PROSTATE CANCER TESTING MARKET Figure 176:Veracyte, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 177:Veracyte, Inc: R&D Expenditure, $Million, 2019-2021 17 All rights reserved at BIS Research Inc.

  18. List of Tables Table 1: Impact Analysis of Market Drivers, Restraints, and Opportunities on the Global Prostate Cancer Testing Market Table 2: Likert Scale Table 3: Numerous Risk Categories for Clinically Localized Prostate Cancer Table 4: Estimated Number of Deaths in 2018 and in 2040 Table 5: Recommendations Related to Prostate Cancer Screening Table 6: Blood-Based Biomarkers for Prostate Cancer Table 7: Guidance and Age Recommendations: Prostate Cancer Table 8: Urine-Based Biomarkers for Prostate Cancer Table 9: PCA3 Test Score Table 10:Tissue-Based Biomarkers for Prostate Cancer GLOBAL PROSTATE CANCER TESTING MARKET 18 All rights reserved at BIS Research Inc.

  19. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have the vision to be a leading and preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Know More Know More Know More GLOBAL PROSTATE CANCER TESTING MARKET Know More 19 All rights reserved at BIS Research Inc.

  20. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published, or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates, and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties, and contingencies. For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 GLOBAL PROSTATE CANCER TESTING MARKET 20 All rights reserved at BIS Research Inc.

  21. GLOBAL PROSTATE CANCER TESTING MARKET BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 21 www.bisresearch.com All rights reserved at BIS Research Inc.

More Related